Literature DB >> 10449064

Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies.

M R Bullock1, B G Lyeth, J P Muizelaar.   

Abstract

Laboratory studies have identified numerous potential therapeutic interventions that might have clinical application for the treatment of human traumatic brain injury. Many of these therapies have progressed into human clinical trials in severe traumatic brain injury. Numerous trials have been completed, and many others have been prematurely terminated or are currently in various phases of testing. The results of the completed Phase III trials have been generally disappointing, compared with the expectations produced by the successes of these interventions in animal laboratory studies. In this review, we summarize the current status of human traumatic brain injury clinical trials, as well as the animal laboratory studies that led to some of these trials. We summarize criteria for conducting clinical trials in severe traumatic brain injury, with suggestions for future improvements. We also attempt to identify factors that might contribute to the discrepancies between animal and human trials, and we propose recommendations that could help investigators avoid certain pitfalls in future clinical trials in traumatic brain injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449064     DOI: 10.1097/00006123-199908000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  31 in total

Review 1.  Level of evidence and citation index in current neurosurgical publications.

Authors:  Ralf D Rothoerl; Joerg Klier; Chris Woertgen; A Brawanski
Journal:  Neurosurg Rev       Date:  2003-06-19       Impact factor: 3.042

Review 2.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

3.  Cognitive evaluation of traumatically brain-injured rats using serial testing in the Morris water maze.

Authors:  Hilaire J Thompson; David G LeBold; Niklas Marklund; Diego M Morales; Andrew P Hagner; Tracy K McIntosh
Journal:  Restor Neurol Neurosci       Date:  2006       Impact factor: 2.406

Review 4.  Critical appraisal of neuroprotection trials in head injury: what have we learned?

Authors:  Christos M Tolias; M Ross Bullock
Journal:  NeuroRx       Date:  2004-01

5.  The expression of CAP1 after traumatic brain injury and its role in astrocyte proliferation.

Authors:  Haiyan Zhang; Yonghua Liu; Yao Li; Ying Zhou; Dongjian Chen; Jianhong Shen; Yaohua Yan; Song Yan; Xinmin Wu; Aihong Li; Aisong Guo; Chun Cheng
Journal:  J Mol Neurosci       Date:  2014-07-25       Impact factor: 3.444

Review 6.  Role of Wnt Signaling in Central Nervous System Injury.

Authors:  Catherine Lambert; Pedro Cisternas; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

Review 7.  [Traumatic brain injury: impact on timing and modality of fracture care].

Authors:  P F Stahel; W Ertel; C E Heyde
Journal:  Orthopade       Date:  2005-09       Impact factor: 1.087

8.  Dosing and safety of cyclosporine in patients with severe brain injury.

Authors:  Jimmi Hatton; Bonnie Rosbolt; Philip Empey; Richard Kryscio; Byron Young
Journal:  J Neurosurg       Date:  2008-10       Impact factor: 5.115

Review 9.  Excitatory amino acid inhibitors for traumatic brain injury.

Authors:  C Willis; S Lybrand; N Bellamy
Journal:  Cochrane Database Syst Rev       Date:  2004

10.  NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats.

Authors:  Hans H Wei; Xi-Chun M Lu; Deborah A Shear; Anu Waghray; Changping Yao; Frank C Tortella; Jitendra R Dave
Journal:  J Neuroinflammation       Date:  2009-08-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.